| tRNA-derived fragments (tRFs) in bladder cancer: increased 5′-tRF-LysCTT results in disease early progression and patients’ poor treatment outcome MA Papadimitriou, M Avgeris, P Levis, EC Papasotiriou, G Kotronopoulos, ... Cancers 12 (12), 3661, 2020 | 34 | 2020 |
| Circulating exosomal miRNAs: clinical significance in human cancers M Avgeris, K Panoutsopoulou, MA Papadimitriou, A Scorilas Expert Review of Molecular Diagnostics 19 (11), 979-995, 2019 | 31 | 2019 |
| Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer M Avgeris, A Tsilimantou, PK Levis, T Rampias, MA Papadimitriou, ... Carcinogenesis 40 (8), 965-974, 2019 | 22 | 2019 |
| miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome MA Papadimitriou, AM Papanota, PG Adamopoulos, KM Pilala, CI Liacos, ... British journal of cancer 126 (1), 79-90, 2022 | 14 | 2022 |
| A cancer-related microRNA signature shows biomarker utility in multiple myeloma AM Papanota, P Karousi, CK Kontos, PI Artemaki, CI Liacos, ... International Journal of Molecular Sciences 22 (23), 13144, 2021 | 13 | 2021 |
| Epi‐miRNAs: Modern mediators of methylation status in human cancers MA Papadimitriou, K Panoutsopoulou, KM Pilala, A Scorilas, M Avgeris Wiley Interdisciplinary Reviews: RNA 14 (2), e1735, 2023 | 9 | 2023 |
| Epigenetic regulation of MIR145 core promoter controls miR-143/145 cluster in bladder cancer progression and treatment outcome KM Pilala, MA Papadimitriou, K Panoutsopoulou, P Barbarigos, P Levis, ... Molecular Therapy-Nucleic Acids 30, 311-322, 2022 | 6 | 2022 |
| Cancer quiescence: non-coding RNAs in the spotlight K Soureas, MA Papadimitriou, K Panoutsopoulou, KM Pilala, A Scorilas, ... Trends in Molecular Medicine 29 (10), 843-858, 2023 | 4 | 2023 |
| Preoperative cell-free DNA (cfDNA) in muscle-invasive bladder cancer treatment outcome MA Papadimitriou, P Levis, G Kotronopoulos, K Stravodimos, M Avgeris, ... Clinical Chemistry 69 (4), 399-410, 2023 | 4 | 2023 |
| ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression MA Papadimitriou, M Avgeris, PK Levis, T Tokas, K Stravodimos, ... Journal of Cancer Research and Clinical Oncology 145, 3075-3087, 2019 | 4 | 2019 |
| miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma MA Papadimitriou, K Soureas, AM Papanota, P Tsiakanikas, ... Journal of Translational Medicine 21 (1), 245, 2023 | 3 | 2023 |
| The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma PI Artemaki, AM Papanota, P Karousi, C Liacos, CK Kontos, D Patseas, ... Blood 134, 5529, 2019 | 2 | 2019 |
| Small RNA‐seq and clinical evaluation of tRNA‐derived fragments in multiple myeloma: Loss of mitochondrial i‐tRFHisGTG results in patients' poor treatment … K Soureas, MA Papadimitriou, P Malandrakis, AM Papanota, ... British Journal of Haematology, 2024 | | 2024 |
| Loss of Mir-221/222 Cluster Expression Results in Short-Term Disease Progression and Poor Post-Treatment Outcome in Multiple Myeloma K Soureas, C Minopoulos, MA Papadimitriou, P Malandrakis, ... Blood 142 (Supplement 1), 3353-3353, 2023 | | 2023 |
| P-401 MiRNA-seq and clinical validation of miR-221/222 cluster in multiple myeloma C Minopoulos, K Soureas, MA Papadimitriou, I Ntanasis-Stathopoulos, ... Clinical Lymphoma Myeloma and Leukemia 23, S262, 2023 | | 2023 |
| P-412 Loss of 3'U-tRFHisGTG in predicting poor survival and treatment outcome in multiple myeloma K Soureas, MA Papadimitriou, I Ntanasis-Stathopoulos, P Malandrakis, ... Clinical Lymphoma Myeloma and Leukemia 23, S268, 2023 | | 2023 |
| Evaluation of the Small Heat Shock Protein Family Members HSPB2 and HSPB3 in Bladder Cancer Prognosis and Progression DD Gianniou, AD Sklirou, MA Papadimitriou, KM Pilala, K Stravodimos, ... International Journal of Molecular Sciences 24 (3), 2609, 2023 | | 2023 |
| P-059: miRNA profiling of CD138+ plasma cells identifies miR-181a-5p overexpression as independent predictor of short-term progression and poor treatment outcome in multiple … MA Papadimitriou, AM Papanota, P Adamopoulos, KM Pilala, CI Liacos, ... Clinical Lymphoma Myeloma and Leukemia 21, S71, 2021 | | 2021 |
